These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The effectiveness of health literacy interventions on the informed consent process of health care users: a systematic review protocol. Perrenoud B; Velonaki VS; Bodenmann P; Ramelet AS JBI Database System Rev Implement Rep; 2015 Oct; 13(10):82-94. PubMed ID: 26571285 [TBL] [Abstract][Full Text] [Related]
5. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing. Wen J; Tao W; Hao S; Zu Y J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635 [TBL] [Abstract][Full Text] [Related]
6. "I Want to Do It, But I Want to Make Sure That I Do It Right." Views of Patients with Parkinson's Disease Regarding Early Stem Cell Clinical Trial Participation. de Melo-MartÃn I; Holtzman M; Hacker KS AJOB Empir Bioeth; 2020; 11(3):160-171. PubMed ID: 32516056 [No Abstract] [Full Text] [Related]
7. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Stryker JE; Wray RJ; Emmons KM; Winer E; Demetri G Patient Educ Couns; 2006 Oct; 63(1-2):104-9. PubMed ID: 16242898 [TBL] [Abstract][Full Text] [Related]
8. Looking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa. Munung NS; Nnodu OE; Moru PO; Kalu AA; Impouma B; Treadwell MJ; Wonkam A Gene Ther; 2024 May; 31(5-6):202-208. PubMed ID: 38012299 [TBL] [Abstract][Full Text] [Related]
9. Study of cohort-specific consent and patient control in phase I cancer trials. Daugherty CK; Ratain MJ; Minami H; Banik DM; Vogelzang NJ; Stadler WM; Siegler M J Clin Oncol; 1998 Jul; 16(7):2305-12. PubMed ID: 9667244 [TBL] [Abstract][Full Text] [Related]
10. Process and strategies for patient engagement and outreach in the Sickle Cell Disease (SCD) community to promote clinical trial participation. Byrnes C; Botello-Harbaum M; Clemons T; Bailey L; Valdes KM; Coleman-Cowger VH J Natl Med Assoc; 2022 Apr; 114(2):211-217. PubMed ID: 35093266 [TBL] [Abstract][Full Text] [Related]
11. Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS), a focus group and decision support tool development project. Tanabe P; Reddin C; Thornton VL; Todd KH; Wun T; Lyons JS Acad Emerg Med; 2010 Aug; 17(8):848-58. PubMed ID: 20670322 [TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
14. Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease. Strong H; Mitchell MJ; Goldstein-Leever A; Shook L; Malik P; Crosby LE Adv Ther; 2017 Aug; 34(8):2007-2021. PubMed ID: 28717861 [TBL] [Abstract][Full Text] [Related]
15. Clinical Trial Decision Making in Pediatric Sickle Cell Disease: A Qualitative Study of Perceived Benefits and Barriers to Participation. Patterson CA; Chavez V; Mondestin V; Deatrick J; Li Y; Barakat LP J Pediatr Hematol Oncol; 2015 Aug; 37(6):415-22. PubMed ID: 25072368 [TBL] [Abstract][Full Text] [Related]
16. Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents. Omondi NA; Ferguson SE; Majhail NS; Denzen EM; Buchanan GR; Haight AE; Labotka RJ; Rizzo JD; Murphy EA J Pediatr Hematol Oncol; 2013 May; 35(4):289-98. PubMed ID: 23612380 [TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. Krishnamurti L; Ross D; Sinha C; Leong T; Bakshi N; Mittal N; Veludhandi D; Pham AP; Taneja A; Gupta K; Nwanze J; Matthews AM; Joshi S; Vazquez Olivieri V; Arjunan S; Okonkwo I; Lukombo I; Lane P; Bakshi N; Loewenstein G J Med Internet Res; 2019 Dec; 21(12):e14462. PubMed ID: 31799940 [TBL] [Abstract][Full Text] [Related]
18. Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing. Locatelli F; Corbacioglu S; Hobbs W; Frangoul H; Walters MC Am J Hematol; 2024 Mar; 99(3):430-438. PubMed ID: 38010293 [TBL] [Abstract][Full Text] [Related]
19. Participant Reactions to a Literacy-Focused, Web-Based Informed Consent Approach for a Genomic Implementation Study. Kraft SA; Porter KM; Duenas DM; Guerra C; Joseph G; Lee SS; Shipman KJ; Allen J; Eubanks D; Kauffman TL; Lindberg NM; Anderson K; Zepp JM; Gilmore MJ; Mittendorf KF; Shuster E; Muessig KR; Arnold B; Goddard KAB; Wilfond BS AJOB Empir Bioeth; 2021; 12(1):1-11. PubMed ID: 32981477 [TBL] [Abstract][Full Text] [Related]
20. Parental attitudes toward research participation in pediatric sickle cell disease. Liem RI; Cole AH; Pelligra SA; Mason M; Thompson AA Pediatr Blood Cancer; 2010 Jul; 55(1):129-33. PubMed ID: 20213846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]